Adicet Bio, Inc. (ACET)
9.59
+0.16
(+1.70%)
USD |
NASDAQ |
Sep 04, 16:00
9.63
+0.04
(+0.42%)
After-Hours: 20:00
Adicet Bio Enterprise Value : -15.56M for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | -15.56M |
| September 03, 2026 | -17.06M |
| September 02, 2026 | -18.65M |
| September 01, 2026 | -18.65M |
| August 31, 2026 | -23.89M |
| August 28, 2026 | -20.52M |
| August 27, 2026 | -20.99M |
| August 26, 2026 | -21.55M |
| August 25, 2026 | -21.08M |
| August 24, 2026 | -22.02M |
| August 21, 2026 | -19.30M |
| August 20, 2026 | -17.53M |
| August 19, 2026 | -16.50M |
| August 18, 2026 | -20.05M |
| August 17, 2026 | -23.52M |
| August 14, 2026 | -26.89M |
| August 13, 2026 | -28.01M |
| August 12, 2026 | -28.01M |
| August 11, 2026 | -28.29M |
| August 10, 2026 | -29.42M |
| August 07, 2026 | -30.63M |
| August 06, 2026 | -31.10M |
| August 05, 2026 | -19.59M |
| August 04, 2026 | -19.12M |
| August 03, 2026 | -18.84M |
| Date | Value |
|---|---|
| July 31, 2026 | -20.05M |
| July 30, 2026 | -20.52M |
| July 29, 2026 | -27.64M |
| July 28, 2026 | -28.57M |
| July 27, 2026 | -29.88M |
| July 24, 2026 | -32.41M |
| July 23, 2026 | -26.51M |
| July 22, 2026 | -25.11M |
| July 21, 2026 | -29.32M |
| July 20, 2026 | -31.47M |
| July 17, 2026 | -29.32M |
| July 16, 2026 | -28.39M |
| July 15, 2026 | -24.08M |
| July 14, 2026 | -22.67M |
| July 13, 2026 | -25.30M |
| July 10, 2026 | -22.67M |
| July 09, 2026 | -21.65M |
| July 08, 2026 | -18.74M |
| July 07, 2026 | -24.83M |
| July 06, 2026 | -20.43M |
| July 02, 2026 | -21.08M |
| July 01, 2026 | -24.64M |
| June 30, 2026 | -24.45M |
| June 29, 2026 | -41.54M |
| June 26, 2026 | -43.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.941B |
| Alnylam Pharmaceuticals, Inc. | 35.27B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 1.989B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.36M |
| Total Expenses (Quarterly) | 21.36M |
| EPS Diluted (Quarterly) | -1.988 |
| Earnings Yield | -120.3% |
| Normalized Earnings Yield | -120.26 |